Transaction DateRecipientSharesTypePriceValue
14th December 2020David R Guyer9,270Open or private sale$7.16$66,373.20
14th December 2020Keith Westby4,527Open or private sale$7.16$32,413.32
12th December 2020David R Guyer17,200Exercise of derivative$0.00
12th December 2020Glenn Sblendorio22,950Exercise of derivative$0.00
12th December 2020David Francis Carroll12,500Exercise of derivative$0.00
12th December 2020Keith Westby12,500Exercise of derivative$0.00
10th December 2020David R Guyer9,602Open or private sale$6.96$66,829.92
10th December 2020Keith Westby3,676Open or private sale$6.96$25,584.96
9th December 2020David Francis Carroll10,000Exercise of derivative$0.00
9th December 2020Keith Westby10,000Exercise of derivative$0.00
Iveric Bio
Iveric Bio logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

The company is developing novel therapeutics to treat diseases of the eye. The company is based in San Francisco and has offices in New York and London.

Ticker: OPHT
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1410939
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $246 M (0%)
Assets, Current: $250 M (94%)
Property, Plant and Equipment, Net: $97 Th (-43%)
Other Assets, Noncurrent: $12 Th (0%)
Assets: $250 M (91%)
Liabilities, Current: $12 M (-8%)
Liabilities: $12 M (-8%)
Common Stock, Value, Issued: $89 Th (78%)
Common Stock, Shares, Issued: $89 M (80%)
Retained Earnings (Accumulated Deficit): $514 M (7%)
Stockholders' Equity (Parent): $238 M (0%)
Liabilities and Equity: $250 M (91%)
Research and Development: $13 M (-51%)
General and Administrative Expenses: $6 M (-44%)
Operating Income/Loss: $19 M (-49%)
Provision for income taxes: $386 Th (-3%)